Free Trial
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel
NASDAQ:PBYI

Puma Biotechnology Q3 2026 Earnings Date & Estimates

Puma Biotechnology logo
$10.29 +0.32 (+3.21%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$10.40 +0.12 (+1.12%)
As of 10/9/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Puma Biotechnology is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Puma Biotechnology in Q3 2026

Puma Biotechnology is expected to post earnings of $0.09 per share on revenue of $57.50 million. In the same quarter a year earlier Puma Biotechnology reported $0.21 per share on revenue of $54.48 million. Puma Biotechnology last reported on August 6, 2026, posting $0.19 per share and beating the $0.04 consensus estimate. Puma Biotechnology has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.09
Expected Revenue
$57.50 million
Prior-Year EPS
$0.21
Prior-Year Revenue
$54.48 million
Expected EPS Growth
-57.1%
Expected Revenue Growth
+5.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.19 (Beat by +$0.15)
Last Quarter Revenue
$56.50 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Puma Biotechnology Q3 2026 Earnings FAQ

Puma Biotechnology (NASDAQ:PBYI) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes.

Puma Biotechnology's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Puma Biotechnology to post earnings of $0.09 per share for Q3 2026.

The consensus revenue estimate for Puma Biotechnology is $57.50 million for Q3 2026.

Puma Biotechnology Earnings Headlines

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026  |  marketscreener.comM
Puma Biotechnology (NASDAQ:PBYI) and Aurinia Pharmaceuticals (NASDAQ:AUPH) Head to Head Analysis
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085993
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
October 10 at 1:00 AM  |  Porter & Company (Ad)
Puma Biotechnology Initiates ALISCA(R)-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
September 18, 2026  |  marketscreener.comM
Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung Cancer
September 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/puma-biotechnology-advances-alisertib-combo-trial-in-small-cell-lung-cancer?utm_source=marketbeat.com&utm_medium=referral
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
September 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260917118471/en/puma-biotechnology-initiates-alisca%c2%ae-lung2-a-phase-ii-trial-of-alisertib-in-combination-with-paclitaxel-for-the-treatment-of-patients-with-advanced-small-cell-lung-cancer/
See More Puma Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Puma Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Puma Biotechnology and other key companies, straight to your email.

About Puma Biotechnology

Puma Biotechnology (NASDAQ:PBYI) is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s primary product is NERLYNX® (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the human epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. Puma has also studied neratinib in other breast cancer settings and in additional HER2-driven cancers, including colorectal cancer, although regulatory approval and availability vary by indication and geography.

Founded in 2010 and headquartered in Los Angeles, Puma Biotechnology operates primarily in oncology. The company’s commercialization activities have centered on the United States, while rights and commercial arrangements for neratinib in certain international markets have involved regional partners. Puma was founded and is led by Alan H. Auerbach, who serves as the company’s chief executive officer and president.

View Puma Biotechnology Profile
Earnings Tools